PoreWise Ingredient
Homosalate
Public databaseHOMOSALATE
Homosalate is an organic UV filter that absorbs UVB. Approved for use in sunscreen, within concentration limits set by regional regulation. The strongest evidence comes from a 2013 human trial: In a randomized controlled community trial of 903 adults under 55, daily use of a broad-spectrum SPF 15+ sunscreen slowed skin aging over 4.5 years: the daily-sunscreen group showed 24% less photoaging than the discretionary-use group (relative odds 0.76, 95% CI 0.59 to 0.98). The trial measured the act of using a broad-spectrum sunscreen. 2013 · 903 people · adults under 55 in Nambour, Australia · PMID 23732711 · The trial assigned a broad-spectrum sunscreen. It ran in Australia at a high-UV latitude and stopped at 4.5 years, and the relative effect was modest (24%). 1 product contains Homosalate, at number 2 of 26 on its ingredient list.
- INCI name:
- HOMOSALATE
- CAS number:
- 118-56-9
- Source:
- PubChem
Functions
Products with this ingredient
Homosalate appears on 1 product ingredient lists, most often around number 2; its highest position is number 2 of 26.
| Product | Brand | Where it sits on the list |
|---|---|---|
| Ultra-Light Moisturizing Lotion SPF 30 | CeraVe | 2 of 26 |
Studies and results
- 1 Skin effectSunscreen and prevention of skin aging: a randomized trial
In a randomized controlled community trial of 903 adults under 55, daily use of a broad-spectrum SPF 15+ sunscreen slowed skin aging over 4.5 years: the daily-sunscreen group showed 24% less photoaging than the discretionary-use group (relative odds 0.76, 95% CI 0.59 to 0.98). The trial measured the act of using a broad-spectrum sunscreen.
Human trial · 2013 · 903 people · adults under 55 in Nambour, Australia · Daily use of a broad-spectrum sunscreen in adults under 55 living in a high-UV climate. · The trial assigned a broad-spectrum sunscreen. It ran in Australia at a high-UV latitude and stopped at 4.5 years, and the relative effect was modest (24%).
- 2 Skin effectThe Influence of Sunscreen Use on Skin Pigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Vitiligo
A 2026 review of the 2015-2025 literature concluded that sun protection plays a central role in the prevention and treatment of pigmentation disorders including melasma and post-inflammatory hyperpigmentation, and that broad-spectrum sunscreens with visible-light protection may enhance protection against hyperpigmentation.
Review article · 2026 · People with melasma, post-inflammatory hyperpigmentation or vitiligo · People managing or preventing pigmentation disorders, particularly melasma and post-inflammatory hyperpigmentation; those with darker skin phototypes (IV-VI) where visible light can worsen hyperpigmentation. · 2026 · People with melasma, post-inflammatory hyperpigmentation or vitiligo. · PMID 42793277
- 3 Legal limitsCosIng — European Commission cosmetic ingredient database
UV filters are permitted up to the maximum concentrations set by each market's regulation.
Official ingredient listing · Products making a sunscreen claim. Limits differ between the EU, the US and China. · Reapplication and the amount applied matter more than the label. · Ingredient database · AVOBENZONE · HOMOSALATE · OCTISALATE
Skin concerns this ingredient has been studied for
The people in each study had that concern.
Common questions
- What does Homosalate do in skincare?
- Homosalate is an organic UV filter that absorbs UVB. Approved for use in sunscreen, within concentration limits set by regional regulation.
- Where does Homosalate sit in these formulas?
- Homosalate appears in 1 product, Ultra-Light Moisturizing Lotion SPF 30, at number 2 of 26 on its ingredient list.
- Which products contain Homosalate?
- Products that contain Homosalate: Ultra-Light Moisturizing Lotion SPF 30.
- How strong is the evidence behind Homosalate?
- 3 findings on Homosalate; the strongest is a 2013 human trial of 903 adults under 55 in Nambour, Australia.
- What did the study on Homosalate measure?
- 2013 · 903 people · adults under 55 in Nambour, Australia · PMID 23732711 · The trial assigned a broad-spectrum sunscreen. It ran in Australia at a high-UV latitude and stopped at 4.5 years, and the relative effect was modest (24%).